Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The transaction was valued at a total of $499,072, with each share priced at $25.65.

Shareholders of Pfizer may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Super Bowl LIX has now ended with the Philadelphia Eagles winning it all. However, they weren't the only winners as we were ...

This year's Super Bowl commercials are going for laughs, with advertisers betting that viewers need a diversion from weighty ...

"Knock Out" features a boy in boxing trunks symbolizing the battle against cancer as LL Cool J's "Mama Said Knock You Out" ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

OpenAI's rebrand balances the technical and the emotional by updating its logo and centering a new typeface called OpenAI ...

MicroStrategy, the business intelligence firm and Bitcoin treasury company co-founded by Michael Saylor has rebranded to ...

Pfizer shares are moving higher on Wednesday as the sector sees volatility amid Robert F. Kennedy Jr.'s nomination as the secretary of the Department of Health and Human Services.

In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...